MedTrace Logo

Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.

NCT01636908 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2021-04-15

No results posted yet for this study

Summary

The purpose of this study is to determine intratumoral concentration of kinase inhibitors upon 2 weeks of treatment in tumor tissue of patients.

Conditions

Interventions

DRUG

Sunitinib

50 mg once daily, oral use, 14 days

DRUG

Sorafenib

400 mg, twice daily, oral use, 14 days

DRUG

Erlotinib

150 mg once daily, oral use, 14 days

DRUG

Everolimus

10 mg once daily, oral use, 14 days

DRUG

Lapatinib

1250 mg once daily, oral use, 14 days

DRUG

Dasatinib

100 mg once daily, oral use, 14 days

DRUG

Pazopanib

800 mg once daily, oral use, 14 days

DRUG

Vemurafenib

960 mg twice daily, oral use, 15-21 days

PROCEDURE

tumor biopsy

PROCEDURE

skin biopsy (optional)

Sponsors & Collaborators

  • Amsterdam UMC, location VUmc

    lead OTHER

Principal Investigators

  • H.M.W. Verheul, MD, PhD · VU Medical Center Amsterdam

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2018-01-01
Completion
2019-12-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01636908 on ClinicalTrials.gov